NCT03973151View on ClinicalTrials.gov

Study of HL-085 in NRAS Mutant Advanced Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 1, 2017

Primary Completion Date

January 18, 2021

Study Completion Date

January 18, 2021

Conditions
Melanoma
Interventions
DRUG

HL-085

HL-085 is one MEK inhibitor.

Trial Locations (2)

100142

Beijing Cancer Hospital, Beijing

Unknown

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Shanghai Kechow Pharma, Inc.

INDUSTRY

NCT03973151 - Study of HL-085 in NRAS Mutant Advanced Melanoma | Biotech Hunter | Biotech Hunter